aid: apnimed
name: Apnimed
description: 'Apnimed is a late-stage clinical-stage pharmaceutical company headquartered
  in Cambridge, Massachusetts, developing novel oral drug therapies for sleep-related
  breathing disorders. Its lead candidate AD109 (Oxnimbi) is a fixed-dose combination
  of an anti-muscarinic and a selective norepinephrine reuptake inhibitor, designed
  to improve upper-airway muscle activity and treat an underlying neuromuscular cause
  of obstructive sleep apnea (OSA) rather than manage it mechanically. The company
  was founded in 2017, partners with Shionogi through the Shionogi-Apnimed Sleep Science
  (SASS) joint venture, and had a New Drug Application for AD109 accepted by the FDA
  in 2026. Apnimed is a drug developer, not a software vendor: it publishes no developer
  portal, API documentation, or machine-readable API artifacts.'
image: https://apnimed.com/wp-content/themes/apnimed/favicon/android-icon-192x192.png
url: https://raw.githubusercontent.com/api-evangelist/apnimed/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profile
x-tier-reason: no-api-surface
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Health Care
- Life Sciences
- Sleep Medicine
- Clinical Trials
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/apnimed-domain-security.yml
- type: Website
  url: https://apnimed.com/
- type: About
  url: https://apnimed.com/about/
- type: Blog
  url: https://apnimed.com/news/
- type: Support
  url: https://apnimed.com/contact-us/
- type: TermsOfService
  url: https://apnimed.com/terms-and-conditions/
- type: PrivacyPolicy
  url: https://apnimed.com/privacy-policy/
- type: InvestorRelations
  url: https://ir.apnimed.com/
- type: Careers
  url: https://apnimed.com/careers/
- type: LinkedIn
  url: https://www.linkedin.com/company/apnimed
- type: SecondaryMarket
  url: https://forgeglobal.com/apnimed_stock/
- type: BlogFeeds
  url: https://apnimed.com/feed/
- type: PressReleases
  url: https://apnimed.com/news/
- type: Research
  url: https://apnimed.com/publications/
- type: LLMsTxt
  url: llms/apnimed-llms.txt
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Apnimed is a clinical-stage drug developer whose product is an oral pill (AD109) for
    obstructive sleep apnea, so there is no software surface to expose; apnimed.com is a
    WordPress marketing site whose full Yoast sitemap lists 24 pages and not one developer,
    API, or documentation page, and api./docs./developer.apnimed.com do not resolve in DNS.
  evidence:
  - url: https://apnimed.com/openapi.json
    status: 404
  - url: https://apnimed.com/llms.txt
    status: 404
  - url: https://apnimed.com/.well-known/agent-card.json
    status: 404
  - url: https://apnimed.com/.well-known/security.txt
    status: 404
  - url: https://api.apnimed.com/openapi.json
    status: 0
  - url: https://ir.apnimed.com/llms.txt
    status: 404
  checked: '2026-08-06'